JP7785004B2 - 皮膚障害の治療に使用するための化合物及び組成物 - Google Patents
皮膚障害の治療に使用するための化合物及び組成物Info
- Publication number
- JP7785004B2 JP7785004B2 JP2022545405A JP2022545405A JP7785004B2 JP 7785004 B2 JP7785004 B2 JP 7785004B2 JP 2022545405 A JP2022545405 A JP 2022545405A JP 2022545405 A JP2022545405 A JP 2022545405A JP 7785004 B2 JP7785004 B2 JP 7785004B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- alkyl
- pharmaceutically acceptable
- independently
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025146979A JP2025175030A (ja) | 2020-01-29 | 2025-09-04 | 皮膚障害の治療に使用するための化合物及び組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062967500P | 2020-01-29 | 2020-01-29 | |
| US62/967,500 | 2020-01-29 | ||
| PCT/US2021/015449 WO2021154966A1 (en) | 2020-01-29 | 2021-01-28 | Compounds and compositions for use in treating skin disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025146979A Division JP2025175030A (ja) | 2020-01-29 | 2025-09-04 | 皮膚障害の治療に使用するための化合物及び組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023512664A JP2023512664A (ja) | 2023-03-28 |
| JP2023512664A5 JP2023512664A5 (https=) | 2024-02-06 |
| JP7785004B2 true JP7785004B2 (ja) | 2025-12-12 |
Family
ID=77079457
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022545405A Active JP7785004B2 (ja) | 2020-01-29 | 2021-01-28 | 皮膚障害の治療に使用するための化合物及び組成物 |
| JP2025146979A Pending JP2025175030A (ja) | 2020-01-29 | 2025-09-04 | 皮膚障害の治療に使用するための化合物及び組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025146979A Pending JP2025175030A (ja) | 2020-01-29 | 2025-09-04 | 皮膚障害の治療に使用するための化合物及び組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11807621B2 (https=) |
| EP (2) | EP4096661B1 (https=) |
| JP (2) | JP7785004B2 (https=) |
| KR (1) | KR102735703B1 (https=) |
| CN (2) | CN118702672A (https=) |
| AU (1) | AU2021212754A1 (https=) |
| CA (1) | CA3168103A1 (https=) |
| ES (1) | ES3032872T3 (https=) |
| HU (1) | HUE071972T2 (https=) |
| IL (2) | IL295088B2 (https=) |
| NZ (1) | NZ790364A (https=) |
| PL (1) | PL4096661T3 (https=) |
| WO (1) | WO2021154966A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021154966A1 (en) | 2020-01-29 | 2021-08-05 | Kamari Pharma Ltd. | Compounds and compositions for use in treating skin disorders |
| KR20250008740A (ko) * | 2022-05-05 | 2025-01-15 | 카마리 파마 리미티드 | 피부 병태 및 이의 증상을 치료하는 방법 |
| CN117164527B (zh) * | 2022-05-25 | 2026-02-17 | 大连理工大学 | 一种钒催化杂环芳香腈水解制备杂环芳香酰胺的方法 |
| KR20250091305A (ko) | 2022-11-10 | 2025-06-20 | 프라임 진 테라퓨틱스 컴퍼니 리미티드 | 질소 함유 스피로 고리 화합물, 약학 조성물 및 이의 용도 |
| WO2024099403A1 (zh) * | 2022-11-10 | 2024-05-16 | 北京普祺医药科技股份有限公司 | 一种具有软药性质的硫醚类化合物、药物组合物及其用途 |
| CN117624036A (zh) * | 2023-10-30 | 2024-03-01 | 爱斯特（成都）生物制药股份有限公司 | 一种制备6-溴-3-氟-2-吡啶甲醛的方法 |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005100341A1 (ja) | 2004-04-15 | 2005-10-27 | Astellas Pharma Inc. | ２－アミノピリミジン誘導体 |
| JP2007515468A (ja) | 2003-12-22 | 2007-06-14 | ファイザー・インク | バソプレシン・アンタゴニストとしてのトリアゾール誘導体 |
| WO2008033564A1 (en) | 2006-09-15 | 2008-03-20 | Hydra Biosciences Inc. | Compounds for modulating trpv3 function |
| JP2009514882A (ja) | 2005-11-02 | 2009-04-09 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | がんおよび他の過剰増殖性疾患の処置のためのピロロ［２，１−ｆ］［１，２，４］トリアジン−４−イルアミンＩＧＦ−１Ｒキナーゼ阻害剤 |
| WO2013118817A1 (ja) | 2012-02-07 | 2013-08-15 | 大鵬薬品工業株式会社 | キノリルピロロピリミジン化合物又はその塩 |
| WO2015152253A1 (ja) | 2014-04-01 | 2015-10-08 | 大日本住友製薬株式会社 | ４－アリールイミダゾール誘導体 |
| JP2016518383A (ja) | 2013-05-01 | 2016-06-23 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ビヘテロアリール化合物及びその使用 |
| US20160272587A1 (en) | 2013-11-08 | 2016-09-22 | The Translational Genomics Research Institute | Compounds for cognitive enhancement and methods of use thereof |
| JP2017530984A (ja) | 2014-10-10 | 2017-10-19 | ジェネンテック， インコーポレイテッド | ヒストンデメチラーゼのインヒビターとしてのピロリドンアミド化合物 |
| US20180194768A1 (en) | 2015-04-24 | 2018-07-12 | President And Fellows Of Harvard College | Substrate selective inhibitors of insulin degrading enzyme (ide) and uses thereof |
| JP2019519534A (ja) | 2016-05-24 | 2019-07-11 | 上海 インスティテュート オブ マテリア メディカ、チャイニーズ アカデミー オブ サイエンシーズＳｈａｎｇｈａｉ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｍａｔｅｒｉａ Ｍｅｄｉｃａ， Ｃｈｉｎｅｓｅ Ａｃａｄｅｍｙ Ｏｆ Ｓｃｉｅｎｃｅｓ | 五員複素環［３，４−ｄ］ピリダジノン系化合物、その製造方法、医薬組成物及び応用 |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2798053A (en) | 1952-09-03 | 1957-07-02 | Goodrich Co B F | Carboxylic polymers |
| US4183931A (en) | 1977-09-08 | 1980-01-15 | Research Corporation | 2-Ketoalkyl-4(3H)-quinazolinones |
| EP0005501B1 (de) | 1978-05-20 | 1981-11-25 | Bayer Ag | Heteroaryl-oxyessigsäureamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide |
| US4461896A (en) | 1979-02-07 | 1984-07-24 | Norwich Eaton Pharmaceuticals, Inc. | 1-[Acylthio) and (mercapto)-1-oxoalkyl]-1,2,3,4-tetrahydroquinoline-2-carboxylic acids |
| DE3018075A1 (de) | 1980-05-10 | 1981-11-12 | Bayer Ag, 5090 Leverkusen | Mittel zur regulierung des pflanzenwachstums, deren herstellung und deren verwendung |
| JPS56158702A (en) | 1980-05-12 | 1981-12-07 | Nippon Tokushu Noyaku Seizo Kk | Herbicide |
| US4273927A (en) | 1980-08-14 | 1981-06-16 | Morton-Norwich Products, Inc. | Converting enzyme inhibitor |
| DE3038599A1 (de) | 1980-10-13 | 1982-05-19 | Bayer Ag, 5090 Leverkusen | Substituierte benzazol-2-yl-oxyessigsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als herbizide |
| DE3038652A1 (de) | 1980-10-13 | 1982-05-19 | Bayer Ag, 5090 Leverkusen | 5-chlor-benzoxazol-2-yl-oxyessigsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als herbizide |
| US4509949A (en) | 1983-06-13 | 1985-04-09 | The B. F. Goodrich Company | Water thickening agents consisting of copolymers of crosslinked acrylic acids and esters |
| DE3418168A1 (de) | 1984-05-16 | 1985-11-21 | Bayer Ag, 5090 Leverkusen | 6-chlorbenzazolyloxyacetamide |
| DE3422861A1 (de) | 1984-06-20 | 1986-01-02 | Bayer Ag, 5090 Leverkusen | Verfahren zur herstellung von heteroaryloxyacetamiden |
| US5087445A (en) | 1989-09-08 | 1992-02-11 | Richardson-Vicks, Inc. | Photoprotection compositions having reduced dermal irritation |
| US5075313A (en) | 1990-09-13 | 1991-12-24 | Eli Lilly And Company | 3-aryl-4(3H)quinazolinone CCK antagonists and pharmaceutical formulations thereof |
| US5196427A (en) | 1990-09-13 | 1993-03-23 | Eli Lilly And Company | 3-aryl-4(3H) quinazolinone CCK antagonists and pharmaceutical formulations thereof |
| DE4218433A1 (de) | 1992-06-04 | 1993-12-09 | Bayer Ag | Fluorbenzoxazolyloxyacetamide |
| DE4219246A1 (de) | 1992-06-12 | 1993-12-16 | Bayer Ag | Neue 2-(7-Chlor-2-benzoxazolyloxy)-acetamide |
| DE4230903A1 (de) | 1992-09-16 | 1994-03-17 | Bayer Ag | Fluorbenzthiazolyloxyacetamide |
| FR2707639B1 (fr) | 1993-06-30 | 1995-10-13 | Pf Medicament | Nouveaux composés indoliques dérivés d'arylamines comme ligands sélectifs des récepteurs 5HT1D et 5HT1B. |
| US5756502A (en) | 1994-08-08 | 1998-05-26 | Warner-Lambert Company | Quinazolinone derivatives as cholyecystokinin (CCK) ligands |
| DE19615262A1 (de) | 1996-04-18 | 1997-10-23 | Bayer Ag | Heteroverknüpfte Phenylglycinolamide |
| CN1103772C (zh) | 1996-05-15 | 2003-03-26 | 辉瑞大药厂 | 新的2,3－二取代－4(3h)－喹唑啉酮类化合物 |
| EP0807633B1 (en) | 1996-05-15 | 2002-11-06 | Pfizer Inc. | Novel 2,3-disubstituted-(5,6)- heteroarylfused-pyrimidine-4-ones |
| TR199902094T2 (xx) | 1997-02-28 | 1999-12-21 | Prizer Products Inc. | 3-Heteroareil-4(3H)-kinazolinonlar�n atropizomerleri. |
| SK113299A3 (en) | 1997-02-28 | 2001-05-10 | Pfizer Prod Inc | Atropisomers of 3-aryl-4(3h)-quinazolinones and their use as ampa-receptor antagonists |
| DE69809827D1 (de) | 1997-03-31 | 2003-01-16 | Korea Res Inst Chem Tech | Chinolinische Sulfid-Derivate als NMDA Rezeptor-Antagonisten und Verfahren zu ihrer Herstellung |
| US6627755B1 (en) | 1997-06-09 | 2003-09-30 | Pfizer Inc | Quinazolin-4-one AMPA antagonists |
| US6060479A (en) | 1997-06-09 | 2000-05-09 | Pfizer Inc | Quinazoline-4-one AMPA antagonists |
| US6323208B1 (en) | 1997-09-05 | 2001-11-27 | Pfizer Inc | Atropisomers of 2,3-disubstituted-(5.6)-heteroaryl fused-pyrimidin-4-ones |
| IL125950A0 (en) | 1997-09-05 | 1999-04-11 | Pfizer Prod Inc | Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy |
| JPH11279158A (ja) | 1998-02-09 | 1999-10-12 | Pfizer Prod Inc | キナゾリン―４―オン誘導体の製造方法 |
| JP4327915B2 (ja) | 1998-03-30 | 2009-09-09 | 株式会社デ・ウエスタン・セラピテクス研究所 | スルフォンアミド誘導体 |
| JP4994552B2 (ja) | 1999-09-16 | 2012-08-08 | キュリス，インコーポレイテッド | ヘッジホッグシグナル伝達経路のメディエーター、組成物及びそれらと関連する利用 |
| US20030219806A1 (en) | 2000-02-22 | 2003-11-27 | Millennium Pharmaceuticals, Inc. | Novel 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 and 33751 molecules and uses therefor |
| AU2001270240A1 (en) | 2000-06-26 | 2002-01-08 | Millennium Pharmaceuticals, Inc. | Human calcium channels (48000; 52920) and uses thereof |
| GB2372993A (en) | 2000-11-03 | 2002-09-11 | Smithkline Beecham Plc | Vanilloid Receptor 6 |
| US20030027164A1 (en) | 2000-12-01 | 2003-02-06 | Gaughan Glen T. | Novel human nucleic acid molecules and polypeptides encoding a novel human ion channel expressed in spinal cord and brain |
| EP1399558A2 (en) | 2001-06-13 | 2004-03-24 | Novartis AG | Vanilloid receptor-related nucleic acids and polypeptides |
| US7053216B2 (en) | 2001-11-19 | 2006-05-30 | Iconix Pharmaceuticals, Inc. | Modulators of Rho C activity |
| US20040110777A1 (en) | 2001-12-03 | 2004-06-10 | Annis Gary David | Quinazolinones and pyridinylpyrimidinones for controlling invertebrate pests |
| US20040009537A1 (en) | 2002-01-11 | 2004-01-15 | Jack Roos | Methods of modulating and of identifying agents that modulate intracellular calcium |
| TW200401770A (en) | 2002-06-18 | 2004-02-01 | Sankyo Co | Fused-ring pyrimidin-4(3H)-one derivatives, processes for the preparation and uses thereof |
| US6649638B1 (en) | 2002-08-14 | 2003-11-18 | Ppd Discovery, Inc. | Prenylation inhibitors and methods of their synthesis and use |
| MXPA05004328A (es) | 2002-11-04 | 2005-08-02 | Nps Pharma Inc | Compuestos de quinazolinona como calciliticos. |
| DE10330157A1 (de) | 2003-07-04 | 2005-02-03 | Zf Friedrichshafen Ag | Lastschaltgetriebe für Baumaschinen, insbesondere für Baggerlader und Telehandler |
| GB0317516D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as PDE4 inhibitors |
| ATE532509T1 (de) | 2003-09-11 | 2011-11-15 | Tibotec Pharm Ltd | Mittel zur hemmung des eintritts des hiv-virus |
| DE10351087A1 (de) | 2003-10-31 | 2005-05-25 | Bayer Technology Services Gmbh | Feste Wirkstoff-Formulierung |
| CA2545725A1 (en) | 2003-11-14 | 2005-06-02 | Merck Sharp & Dohme Limited | Bicyclic pyrimidin-4-(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (vr1) |
| EP1722783A4 (en) | 2004-03-08 | 2009-08-12 | Wyeth Corp | MODULATORS OF THE ION CHANNEL FUNCTION |
| US20050202539A1 (en) | 2004-03-11 | 2005-09-15 | Hydra Biosciences | System for screening eukaryotic membrane proteins |
| EP1750715A1 (en) | 2004-06-04 | 2007-02-14 | Icos Corporation | Methods for treating mast cell disorders |
| EP1790131B1 (en) | 2004-09-09 | 2012-12-05 | Avaya Inc. | Methods of and systems for network traffic security |
| AR051596A1 (es) | 2004-10-26 | 2007-01-24 | Irm Llc | Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios |
| GB0503646D0 (en) * | 2005-02-22 | 2005-03-30 | Novartis Ag | Organic compounds |
| EP2392328A1 (en) | 2005-05-09 | 2011-12-07 | Hydra Biosciences, Inc. | Compounds for modulating TRPV3 Function |
| US8916550B2 (en) | 2005-05-09 | 2014-12-23 | Hydra Biosciences, Inc. | Compounds for modulating TRPV3 function |
| GB0509573D0 (en) | 2005-05-11 | 2005-06-15 | Merck Sharp & Dohme | Therapeutic compounds |
| US20090298856A1 (en) | 2005-05-11 | 2009-12-03 | Rebecca Elizabeth Brown | 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) |
| TW200726767A (en) * | 2005-07-04 | 2007-07-16 | Astrazeneca Ab | Chemical compounds 2 |
| US7893260B2 (en) | 2005-11-04 | 2011-02-22 | Hydra Biosciences, Inc. | Substituted quinazolin-4-one compounds for antagonizing TRPV3 function |
| WO2008140750A1 (en) | 2007-05-10 | 2008-11-20 | Hydra Biosciences Inc. | Compounds for modulating trpv3 function |
| US20090306163A1 (en) | 2008-06-10 | 2009-12-10 | Pamela Renee Lipkin | Topical compositions comprising imidazolidinedione analogs and their use to treat or prevent the appearance of skin wrinkling |
| KR101034300B1 (ko) | 2008-12-02 | 2011-05-16 | 고려대학교 산학협력단 | Ｔｒｐｖ３ 활성 억제 약물 및 이의 활용 |
| US8318928B2 (en) * | 2008-12-15 | 2012-11-27 | Glenmark Pharmaceuticals, S.A. | Fused imidazole carboxamides as TRPV3 modulators |
| US8318759B2 (en) * | 2009-02-18 | 2012-11-27 | Hoffmann-La Roche Inc. | Pyrrolidine derivatives as NK3 receptor antagonists |
| US8614242B2 (en) * | 2010-10-21 | 2013-12-24 | Bayer Intellectual Property Gmbh | 1-(heterocyclic carbonyl)-2-substituted pyrrolidines |
| EP2632551B1 (en) * | 2010-10-28 | 2016-07-06 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| US20140018435A1 (en) | 2012-06-06 | 2014-01-16 | University Of Illinois Chicago | Transdermal Delivery of Therapeutic Agents Using Poly (Amidoamine) Dendrimers |
| US9562035B2 (en) * | 2013-12-03 | 2017-02-07 | Janssen Pharmaceutica Nv | Benzamide derivative useful as FASN inhibitors for the treatment of cancer |
| CN108570038B (zh) | 2017-03-08 | 2021-09-28 | 中国科学院上海药物研究所 | 二氢喹喔啉类溴结构域识别蛋白抑制剂及制备方法和用途 |
| WO2021154966A1 (en) | 2020-01-29 | 2021-08-05 | Kamari Pharma Ltd. | Compounds and compositions for use in treating skin disorders |
| KR20250008740A (ko) * | 2022-05-05 | 2025-01-15 | 카마리 파마 리미티드 | 피부 병태 및 이의 증상을 치료하는 방법 |
-
2021
- 2021-01-28 WO PCT/US2021/015449 patent/WO2021154966A1/en not_active Ceased
- 2021-01-28 AU AU2021212754A patent/AU2021212754A1/en active Pending
- 2021-01-28 CA CA3168103A patent/CA3168103A1/en active Pending
- 2021-01-28 ES ES21748179T patent/ES3032872T3/es active Active
- 2021-01-28 KR KR1020227025104A patent/KR102735703B1/ko active Active
- 2021-01-28 EP EP21748179.5A patent/EP4096661B1/en active Active
- 2021-01-28 JP JP2022545405A patent/JP7785004B2/ja active Active
- 2021-01-28 HU HUE21748179A patent/HUE071972T2/hu unknown
- 2021-01-28 US US17/160,802 patent/US11807621B2/en active Active
- 2021-01-28 NZ NZ790364A patent/NZ790364A/en unknown
- 2021-01-28 IL IL295088A patent/IL295088B2/en unknown
- 2021-01-28 EP EP25165470.3A patent/EP4574822A3/en active Pending
- 2021-01-28 CN CN202410539437.6A patent/CN118702672A/zh active Pending
- 2021-01-28 CN CN202180024047.XA patent/CN115335050B/zh active Active
- 2021-01-28 PL PL21748179.5T patent/PL4096661T3/pl unknown
-
2023
- 2023-04-13 US US18/300,234 patent/US12435061B2/en active Active
-
2025
- 2025-09-04 JP JP2025146979A patent/JP2025175030A/ja active Pending
- 2025-10-19 IL IL324069A patent/IL324069A/en unknown
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007515468A (ja) | 2003-12-22 | 2007-06-14 | ファイザー・インク | バソプレシン・アンタゴニストとしてのトリアゾール誘導体 |
| WO2005100341A1 (ja) | 2004-04-15 | 2005-10-27 | Astellas Pharma Inc. | ２－アミノピリミジン誘導体 |
| JP2009514882A (ja) | 2005-11-02 | 2009-04-09 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | がんおよび他の過剰増殖性疾患の処置のためのピロロ［２，１−ｆ］［１，２，４］トリアジン−４−イルアミンＩＧＦ−１Ｒキナーゼ阻害剤 |
| WO2008033564A1 (en) | 2006-09-15 | 2008-03-20 | Hydra Biosciences Inc. | Compounds for modulating trpv3 function |
| WO2013118817A1 (ja) | 2012-02-07 | 2013-08-15 | 大鵬薬品工業株式会社 | キノリルピロロピリミジン化合物又はその塩 |
| JP2016518383A (ja) | 2013-05-01 | 2016-06-23 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ビヘテロアリール化合物及びその使用 |
| US20160272587A1 (en) | 2013-11-08 | 2016-09-22 | The Translational Genomics Research Institute | Compounds for cognitive enhancement and methods of use thereof |
| WO2015152253A1 (ja) | 2014-04-01 | 2015-10-08 | 大日本住友製薬株式会社 | ４－アリールイミダゾール誘導体 |
| JP2017530984A (ja) | 2014-10-10 | 2017-10-19 | ジェネンテック， インコーポレイテッド | ヒストンデメチラーゼのインヒビターとしてのピロリドンアミド化合物 |
| US20180194768A1 (en) | 2015-04-24 | 2018-07-12 | President And Fellows Of Harvard College | Substrate selective inhibitors of insulin degrading enzyme (ide) and uses thereof |
| JP2019519534A (ja) | 2016-05-24 | 2019-07-11 | 上海 インスティテュート オブ マテリア メディカ、チャイニーズ アカデミー オブ サイエンシーズＳｈａｎｇｈａｉ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｍａｔｅｒｉａ Ｍｅｄｉｃａ， Ｃｈｉｎｅｓｅ Ａｃａｄｅｍｙ Ｏｆ Ｓｃｉｅｎｃｅｓ | 五員複素環［３，４−ｄ］ピリダジノン系化合物、その製造方法、医薬組成物及び応用 |
Non-Patent Citations (3)
| Title |
|---|
| PubChem [online]，2011年03月29日，検索日：2024年10月21日,SID-116084532,<https:/ /pubchem.ncbi.nlm.nih.gov/substance/116084532 |
| PubChem [online]，2015年02月12日，検索日：2024年10月21日,SID-230369822,<https:/ /pubchem.ncbi.nlm.nih.gov/substance/230369822 |
| Wuyue SU et al.，"TRPV3: Structure, Diseases and Modulators", Molecules，2023年01月12日，Vol. 28, No. 2，p.774，DOI: 10.3390/molecules28020774 |
Also Published As
| Publication number | Publication date |
|---|---|
| IL295088B1 (en) | 2025-12-01 |
| AU2021212754A1 (en) | 2022-08-04 |
| EP4574822A2 (en) | 2025-06-25 |
| US20220332697A1 (en) | 2022-10-20 |
| WO2021154966A1 (en) | 2021-08-05 |
| US11807621B2 (en) | 2023-11-07 |
| EP4096661A1 (en) | 2022-12-07 |
| KR20220139299A (ko) | 2022-10-14 |
| CN115335050B (zh) | 2024-05-17 |
| JP2025175030A (ja) | 2025-11-28 |
| EP4574822A3 (en) | 2025-08-27 |
| PL4096661T3 (pl) | 2025-09-01 |
| ES3032872T3 (en) | 2025-07-28 |
| EP4096661A4 (en) | 2024-03-06 |
| BR112022014933A2 (pt) | 2022-09-20 |
| KR102735703B1 (ko) | 2024-11-28 |
| CN118702672A (zh) | 2024-09-27 |
| IL324069A (en) | 2025-12-01 |
| NZ790364A (en) | 2025-12-19 |
| IL295088B2 (en) | 2026-04-01 |
| EP4096661B1 (en) | 2025-04-02 |
| CA3168103A1 (en) | 2021-08-05 |
| US12435061B2 (en) | 2025-10-07 |
| CN115335050A (zh) | 2022-11-11 |
| US20240124413A1 (en) | 2024-04-18 |
| JP2023512664A (ja) | 2023-03-28 |
| EP4096661C0 (en) | 2025-04-02 |
| HUE071972T2 (hu) | 2025-10-28 |
| IL295088A (en) | 2022-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7785004B2 (ja) | 皮膚障害の治療に使用するための化合物及び組成物 | |
| CN110300589B (zh) | 作为cftr增效剂的双环异杂芳基衍生物 | |
| CN105263326B (zh) | 甲基/氟-吡啶基-甲氧基取代的吡啶酮-吡啶基化合物及氟-嘧啶基-甲氧基取代的吡啶酮-吡啶基化合物 | |
| US11319317B2 (en) | (Hetero)arylamide compound for inhibiting protein kinase activity | |
| TW201443042A (zh) | 作為激酶抑制劑之雜環醯胺類 | |
| EP2634188A1 (en) | Fused aminodihydropyrimidine derivative | |
| WO2017114383A1 (zh) | 一类新型的egfr野生型和突变型的激酶抑制剂 | |
| CA3177164A1 (en) | Bicyclic kinase inhibitors and uses thereof | |
| WO2019154252A1 (zh) | 取代的烟酰胺类化合物及药物组合物及其用途 | |
| CN102083817A (zh) | 作为itpkb抑制剂的化合物和组合物 | |
| US11091462B2 (en) | (Hetero)arylamide compound for inhibiting protein kinase activity | |
| TW201249825A (en) | Novel compounds | |
| HK40082455A (en) | Compounds and compositions for use in treating skin disorders | |
| BR122024002638B1 (pt) | Compostos e usos destes | |
| BR122024002638A2 (pt) | Compostos, composições compreendendo os mesmos, e usos destes | |
| BR112022014933B1 (pt) | Compostos ou sal farmaceuticamente aceitável dos mesmos e usos dos mesmos | |
| HK40082455B (zh) | 用於治疗皮肤病症的化合物和组合物 | |
| JP2020519694A (ja) | オレキシン受容体アンタゴニス | |
| CN109863147B (zh) | 具有erk激酶抑制活性的化合物及其用途 | |
| CN115427399A (zh) | 2-杂芳基氨基喹唑啉酮衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240126 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240126 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20241212 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20241220 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250319 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250605 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250904 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20251104 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20251202 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7785004 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |